← All trials
NCT05273307
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 4, 2022
- Primary completion
- Apr 30, 2024
- Completion date
- Apr 30, 2025
- First posted
- Mar 10, 2022
- Last posted
- Jun 28, 2022
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, San FranciscoLead sponsor
- Mount Zion Health FundCollaborator
- University of California, San FranciscoOverall official - principal investigator
- University of California, San FranciscoOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.